Cartesian Therapeutics: Barclays reports 0.02% stake

The ownership table lists shared voting and dispositive power over 19,462 shares each, alongside a separate beneficial-ownership figure of 7,233 shares.

Available on EDGAR 11/06/2026 - 03:45 PM EST Accepted by SEC EDGAR 11/06/2026 - 03:44 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Barclays PLC’s amendment for Cartesian Therapeutics, Inc. (RNAC) reports beneficial ownership of 7,233 common shares, or 0.02% of the class, as of September 30, 2026. It separately lists shared voting and dispositive power over 19,462 shares each and sole voting and dispositive power of zero.

Key Figures

Beneficial ownership: 7,233 shares Percent of class: 0.02% Shared voting power: 19,462 shares +1 more

4 metrics

Beneficial ownership 7,233 shares As of September 30, 2026

Percent of class 0.02% As of September 30, 2026

Shared voting power 19,462 shares Ownership reported as of September 30, 2026

Shared dispositive power 19,462 shares Ownership reported as of September 30, 2026

Key Terms

beneficially owned, Shared Voting Power, Shared Dispositive Power

3 terms

beneficially owned regulatory

"Amount beneficially owned: 7233"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared Voting Power regulatory

"Shared Voting Power 19,462.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

Shared Dispositive Power regulatory

"Shared Dispositive Power 19,462.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RNAC shares did Barclays PLC report beneficially owning?

Barclays PLC reported beneficial ownership of 7,233 Cartesian Therapeutics common shares, representing 0.02% of the class, as of September 30, 2026.

How much shared voting power did Barclays PLC report over RNAC shares?

The ownership section lists shared voting power over 19,462 shares and shared dispositive power over 19,462 shares. Sole voting and dispositive power are each listed as zero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CARTESIAN THERAPEUTICS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

816212302

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 816212302

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 19,462.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 19,462.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,233.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.02 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CARTESIAN THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 7495 New Horizon Way
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP No.: 816212302
Item 4.	Ownership
(a)	Amount beneficially owned: 7233
(b)	Percent of class: 0.02 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 19462
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 19462
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	11/06/2026